References
Wooley, O.H., Griffin, J., Panayi, G.S., Batchelor, J.R., Welsh, K.I., Gibson, T.J., HLA-DR antigens and toxic reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980, 303, 300–302.
Perrier, P., Raffoux, C., Thomas, Ph., Tamisier, J.N., Busson, M., Gaucher, A., Streiff, F., HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis. Ann Rheum Dis, 1985, 44, 621–624.
Ayesh, R., Mitchell, S. C., Waring, R.H., Withrington, R.H., Seifert, M.H., Smith, L. Sodium aurothiomalate toxicity and sulphoxidation capacity in rheumatoid arthritis patients Br J Rheumatol 1987, 26, 197–201.
Madhok, R., Capell, H.A., Waring, R. Does sulphoxidation state predict gold toxicity in rheumatoid arthritis? Br Med J 1987, 294, 483.
Srinivasan, R., Miller, B.L., Paulus, H.E. Long-term chrysotherapy in rheumatoid arthritis. Arthritis Rheum. 1979, 22, 105–110.
Evers, A.E., Sundstrom, W.R. Second course gold therapy in the treatment of rheumatoid arthritis. Arthritis Rheum. 1983, 26, 1071–1075.
Williame, L.M.E., Joos, R., Proot, F., Immesoete, C. Gold induced aplastic anaemia. Clin Rheumatol 1987, 6, 4, 600–605.
Rubinstein, I., Langevitz, P., Pras, M., Aurothio-glucose overdosage in five patients with rheumatoid arthritis. Clin Rheumatol 1987, 6, 4, 583–587.
Anon. Methotrexate for arthritis. Lancet, 1986, 1, 74–75.
Weinstein, A. Reappraisal of the use of methotrexate in the management of rheumatoid arthritis. Int Med Special, 1986, 7, 79–84.
Willkens, R.F., Williams, H.J., Egger, M.J., Reading, J. C., Clements, P. J., Cathcart, E.S., Samuelson, C.O. Jr., Solsky, M.A., Kaplan, S.B., Guttadauria, M., Halla, J.T., Weinstein, A. Randomized, double-blind, placebo controlled trial of lowdose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984, 27, 376–381.
Leonard, P.A., Clegg, D.O., Carson, C., Cannon, G.W., Egger, M.J., Ward, J.R. Low dose pulse methotrexate in rheumatoid arthritis: an 8 year experience with hepatotoxicity. Clin Rheumatol 1987, 6, 4, p. 575–582.
Weinstein, A., Marlowe, S., Korn, J., Farouhar, F. Low dose methotrexate treatment of rheumatoid arthritis: long-term observations. Am J Med 1985, 79, 331–337.
Bitter, T. Combined disease-modifying chemotherapy for intractable rheumatoid arthritis. Clin Rheum Dis 1984, 10, 417–428.
McCarty, D.J., Carrera, G.F. Intractable rheumatoid Arthritis: treatment with combined cyclophosphamide, azathioprine and hydroxychloroquine. J A M A 1982, 248, 1718–1723.
Binder, A.I., SO, A., Ansell, B.M., Denman, A.M. Intensive immunosuppression in intractable rheumatoid arthritis. Br J Rheumatol 1986, 25, 380–383.
Rights and permissions
About this article
Cite this article
Disease-modifying drugs for rheumatoid arthritis Asset or liability?. Clin Rheumatol 6, 486–488 (1987). https://doi.org/10.1007/BF02330584
Issue Date:
DOI: https://doi.org/10.1007/BF02330584